World Health Organization Raises Concern Over Critical Scarcity of Obesity Medications
Under a tenth of individuals who could benefit from GLP-1 drugs such as Wegovy are able to get them, warns the WHO as it releases its inaugural recommendations on the therapies.
Given in excess of 1,000,000,000 people worldwide now obese, it is urging more widespread and fairer access to GLP-1 medication.
Based on forecasts, over two billion could be obese by 2030 unless action is taken.
"The new guidelines affirms that obesity is a lifelong illness that can be treated with comprehensive and continuous care," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are major obstacles to widespread access to the injections that can assist patients in reducing substantial body mass, explains the organization.
GLP-1 Therapy Supply Crisis
Even under the present most optimistic case, the supply of these medications could only cover approximately 100 million people – less than 10% of eligible patients, per the health organization.
The advice urges countries and companies to expand access, via strategies like patent sharing.
Exclusive production rights on a key compound – the core ingredient of a leading brand – is scheduled to end in a number of countries in 2026.
The Way Weight-Loss Injections Function
The injections replicate a body's own hormone to reduce digestion speed, reduce hunger and enhance satiety so people reduce food intake.
Individuals usually start to lose weight within a few weeks of commencing the once-weekly jabs.
Research suggests people may put most of the weight back on a year later of stopping the treatment, when their usual hunger resume.
To be above a healthy weight raises your risk for contracting medical conditions, including type 2 diabetes, cardiovascular issues, stroke, and some malignancies.
Excess weight concerns individuals in all nations and was responsible for over three and a half million deaths worldwide in 2024, according to the health agency.
